Pharma M&A fuels more hedge fund returns; Fabry market set to almost double;

@FiercePharma: Novartis goes '80s with Cyndi Lauper-led psoriasis campaign. FiercePharmaMarketing story | Follow @FiercePharma

@EricPFierce: ICYMI last week: Aprecia is building $25M plant where it will do 3D printing of drugs. Article | Follow @EricPFierce

@CarlyHFierce: ICYMI Friday: Orexigen picks up new trial tab to settle Contrave dispute with partner Takeda. More | Follow @CarlyHFierce

> Pharma deals, including AbbVie's ($ABBV) deal for Pharmacyclics and Valeant's ($VRX) buyout of Salix Pharmaceuticals, are boosting returns at hedge funds betting on M&A. Report

> The market for Fabry Disease drugs will mushroom to $1.25 billion by 2024 from $683 million last year as awareness and diagnosis improve, GlobalData says. Report

> At-risk patients say they are having trouble persuading their doctors to prescribe Gilead Sciences' ($GILD) Truvada as a preventive against HIV, despite the FDA's approval for that use. Report

> A new Senate bill expanding protection for whistleblowers could make life more difficult for pharma companies looking to comply with antitrust laws. Report

Medical Device News

@FierceMedDev: UPDATED with interview of CEO: TAVR maker JenaValve receives $26.5M to fund U.S. studies. Report | Follow @FierceMedDev

@VarunSaxena2: Crowdsourcing challenge winner looking to commercialize NIH tech to diagnose brain cancer. Article | Follow @VarunSaxena2

@EmilyWFierce: Congress urges feds to probe FDA over morcellator safety concerns. More | Follow @EmilyWFierce

> Bill introduced to fix FDA's combination product regs; attorneys say it doesn't go far enough. Story

> Sisu to put emergency blood recycling device through trials later this year. Article

Biotech News

@FierceBiotech: AstraZeneca offers $727M package to partner with Inovio on immuno-oncology. News | Follow @FierceBiotech

@JohnCFierce: Sanofi takes another stab at cancer with Evotec, Apeiron checkpoint partnership. Article | Follow @JohnCFierce

@DamianFierce: Like most people, I'm waiting for Thug_BioAnalyst to weigh in before I form an opinion on anything this morning. | Follow @DamianFierce

> Karyopharm tanks as sepsis scares plague its cancer contender. Article

> Sorrento's biotech buyouts bag CAR-T drugs. Item

> Gates backs a $120M breakout round for CRISPR/Cas9 pioneers at Editas. Story

Animal Health News

> Aratana continues to trim losses in Q2 as it focuses on animal treatments. News

> Merck to partner with National Milk Producers group on training and animal care. Report

> USDA grants conditional license to Zoetis for canine anti-itch therapy. Story

> Feds indict four with smuggling bogus pet products into the U.S. Item

> Dechra to buy control of Croatian animal vaccine maker for $56.4M. Article

Biotech IT News

> Apple's ResearchKit goes global as heart study expands into Hong Kong and U.K. Item

> IBM makes $1B bid for Merge to bolster Watson's image analytics capabilities. Report

> Teva buys majority stake in Immuneering to access genome analysis tools. More

> Illumina strikes deal to buy LIMS provider GenoLogics. Article

> FDA makes its first approval of a 3D-printed drug. Story

Pharma Marketing News

> Allergan plots Namzaric DTC campaign to shore up its Namenda defenses. Item

> Amarin case could unleash a flood of off-label promos. Report

> Novartis goes '80s with Cyndi Lauper-led psoriasis campaign. More

> Xtandi marketer Astellas scrums with rugby partners for prostate cancer awareness. Story

> Big Pharma feeds controversy by routing big bucks to private CME. Article

And Finally... Amid consumer worries over their safety, Johnson & Johnson ($JNJ) and Colgate/Palmolive are phasing out microbeads from their personal care products. Report